Skip to main content
. 2023 May 30;24(11):9516. doi: 10.3390/ijms24119516

Figure 4.

Figure 4

Morbidity assessment of pit viper venoms and its neutralisation by commercial antivenoms. (A) MHD of C. malabaricus venom, and the (B) MHD-ED50 of Premium Serum and (C) Sri Lankan antivenoms against it. (D) MHD of H. hypnale venom, (E) MHD-ED50 of the Premium Serum and (F) Sri Lankan antivenom against it. (G) MND of H. hypnale venom, and (H) MND-ED50 of Premium Serum, and (I) Sri Lankan antivenoms against it.